Report of Foreign Issuer (6-k)
December 08 2017 - 4:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
December 2017
Commission file number: 001-36288
Akari
Therapeutics, Plc
(Translation of registrant's name into English)
24 West 40
th
Street, 8
th
Floor
New York, NY 10018
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x
Form
40-F
¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
On December 4, 2017, Akari Therapeutics,
Inc. (the “Company”) terminated Robert Shaw’s employment by the Company as Chief Legal & Compliance Officer
and Company Secretary without cause. Mr. Shaw will remain employed by the Company until January 3, 2018.
The information contained in this report
(including the exhibit hereto) is hereby incorporated by reference into all effective registration statements filed by the Company
under the Securities Act of 1933.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Akari Therapeutics, Plc
|
|
|
(Registrant)
|
|
|
|
|
|
|
By:
|
/s/ David Horn Solomon
|
|
|
Name:
|
David Horn Solomon
|
|
|
|
Chief Executive Officer
|
|
Date: December 8, 2017
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Apr 2023 to Apr 2024